MedPath

Blood Flow Within Active Myofascial Trigger Points Following Massage

Not Applicable
Completed
Conditions
Myofascial Pain
Tension-type Headache
Interventions
Other: Trigger point release
Other: Ultrasound
Registration Number
NCT02389140
Lead Sponsor
University of Colorado, Denver
Brief Summary

The physiological response at the myofascial trigger point (MTrP) to massage is not known, yet would provide important objective evidence for a treatment effect and clarify the resolution process of a MTrP.

Detailed Description

The physiological response at the myofascial trigger point (MTrP) to massage is not known, yet would provide important objective evidence for a treatment effect and clarify the resolution process of a MTrP. The long-term goal is to understand how therapeutic intervention affects the physiology of the MTrP. The objective of the proposed research is to assess, in a placebo controlled trial, the effectiveness of trigger point release massage (also known as ischemic compression) on blood flow at an active MTrP. The central hypothesis is that the contraction nodule of an active MTrP is characterized by an ischemic state comprised of reduced blood flow and subsequent dysregulation in carbohydrate metabolism. The investigators hypothesize that trigger point release (TPR) can positively impact blood flow leading to a change in high energy carbohydrate tension. The present study has been formulated, in part, from a preliminary study conducted by the investigators, which supports reduced blood flow and physiological disruption at active MTrPs. The proposed research will provide a physiological basis for massage to corroborate subjective reports of reduced pain sensitivity, impart credibility to treatment techniques, and provide insight into a mechanism of action for healing the MTrP.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Chronic or episodic tension-type headache
  • active MTrP in upper trapezius
  • age 21-49
  • BMI between 18.5-24.9
  • either gender
  • any race or ethnicity
Read More
Exclusion Criteria
  • No or latent MTrP in the upper trapezius
  • migraine 4+/month
  • cluster headache
  • fibromyalgia
  • neurological disease (e.g. Alzheimer's disease, Parkinson's disease, muscular dystrophy, multiple sclerosis)
  • cardiovascular disease (e.g. prior heart attack or stroke)
  • diabetes
  • pregnancy
  • a bleeding disorder (Self-report of hemophilia, known lack/deficiency of clotting factors, or presently °taking anti-coagulants (e.g. warfarin, Coumadin))
  • narcotic use
  • currently receiving massage
  • prior trigger point injection or needling therapies
  • allergy to lidocaine-type anesthetics such as lidocaine and prilocaine
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Trigger point treatmentTrigger point releaseTrigger point release
UltrasoundUltrasoundSham US at Trigger point
Primary Outcome Measures
NameTimeMethod
Change in Blood Flow as measured by microdialysis1 hr pre intervention and 1 hr post intervention
Secondary Outcome Measures
NameTimeMethod
Change in Glucose as measured by microdialysis1 hr pre intervention and 1 hr post intervention
Change in Lactate as measured by microdialysis1 hr pre intervention and 1 hr post intervention
Change in Pyruvate as measured by microdialysis1 hr pre intervention and 1 hr post intervention

Trial Locations

Locations (1)

University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath